Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Hrzenjak, A; Moinfar, F; Kremser, ML; Strohmeier, B; Staber, PB; Zatloukal, K; Denk, H.
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Mol Cancer Ther. 2006; 5(9):2203-2210 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Denk Helmut
Hrzenjak Andelko
Moinfar Farid
Staber Philipp Bernhard
Zatloukal Kurt
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Covalent modifications of histone proteins, in particular deacetylation of lysine residues, are important for the regulation of gene transcription both in normal and malignant cells. These processes are controlled by histone acetyltransferases and histone deacetylases (HDAC) and have up to now not been described in solid mesenchymal tumors. The present study shows differences in the HDAC1 and HDAC2 expression in endometrial stromal sarcomas (ESS) and a cognate cell line (ESS-1) compared with nonneoplastic endometrial stroma. We show for the first time that HDAC2 expression is consistently increased in ESS. In contrast, HDAC1 expression is generally lower than HDAC2 both in nonneoplastic stroma and in ESS, suggesting that these two proteins, although closely related, are regulated in different ways. In vitro experiments with an ESS cell line showed that valproate, an inhibitor of the class I HDACs, led to significant HDAC2 decrease and to cell differentiation. HDAC2 inhibition in ESS-1 cells caused significant changes in the cell cycle by inhibiting G1-S transition and influencing expression of p21WAF1 and cyclin D1. Moreover, in ESS-1 cells, increased expression of the p21WAF1 was associated with reduction of HDAC2 expression after transfection with small interfering RNA directed against HDAC2. Our results suggest that HDAC2 might be considered as potential drug target in the therapy of ESS and that HDAC inhibitors should be further evaluated in clinical trials in ESS.
Find related publications in this database (using NLM MeSH Indexing)
Cell Differentiation - drug effects
Cell Growth Processes - drug effects
Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis Cyclin-Dependent Kinase Inhibitor p21 - genetics
Endometrial Neoplasms - drug therapy Endometrial Neoplasms - enzymology Endometrial Neoplasms - genetics Endometrial Neoplasms - pathology
Female -
Histone Deacetylase 1 -
Histone Deacetylase 2 -
Histone Deacetylase Inhibitors -
Histone Deacetylases - biosynthesis Histone Deacetylases - genetics
Humans -
Immunohistochemistry -
RNA, Small Interfering - genetics
Repressor Proteins - antagonists and inhibitors Repressor Proteins - biosynthesis Repressor Proteins - genetics
Sarcoma, Endometrial Stromal - drug therapy Sarcoma, Endometrial Stromal - enzymology Sarcoma, Endometrial Stromal - genetics Sarcoma, Endometrial Stromal - pathology
Tumor Cells, Cultured -
Valproic Acid - pharmacology

© Meduni Graz Impressum